PriceTargets.com logo

NASDAQ:BMRA - Biomerica Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.50
  • Forecasted Upside: 109.09 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.50 As of 10/19/2021 05:00 PM ET
▼ -0.18 (-3.17%)

This chart shows the closing price for BMRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biomerica Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BMRA

Analyst Price Target is $11.50
▲ +109.09% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Biomerica in the last 3 months. The average price target is $11.50, with a high forecast of $13.00 and a low forecast of $10.00. The average price target represents a 109.09% upside from the last price of $5.50.

This chart shows the closing price for BMRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Biomerica. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/27/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/26/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/24/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/1/2021Colliers SecuritiesReiterated RatingBuy$13.00High
8/30/2021Colliers SecuritiesReiterated RatingBuy$13.00Low
1/12/2021B. RileyLower Price TargetBuy$11.00 ➝ $10.00High
11/10/2020Colliers SecuritiesInitiated CoverageBuy$13.00High
10/19/2020AegisLower Price TargetBuy$13.00 ➝ $11.00Low
9/4/2020AegisBoost Price TargetBuy$10.00 ➝ $13.00High
8/21/2020AegisInitiated CoverageBuy$10.00Low
6/5/2020B. RileyBoost Price Target$6.25 ➝ $11.00High
10/21/2019B. RileySet Price TargetBuy$6.30Low
9/10/2019B. RileySet Price TargetBuy$6.00High
7/19/2019B. RileySet Price TargetBuy$6.00N/A
12/17/2018B. RileyLower Price TargetBuy ➝ Buy$7.50 ➝ $6.25Medium
1/4/2018B. RileyInitiated CoverageBuy ➝ Buy$7.50High
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/23/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/22/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/22/2021
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
8/21/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/20/2021
  • 4 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
10/20/2021

Current Sentiment

  • 4 very positive mentions
  • 23 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Biomerica logo
Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.
Read More

Today's Range

Now: $5.50
Low: $5.32
High: $6.10

50 Day Range

MA: $4.77
Low: $3.90
High: $6.71

52 Week Range

Now: $5.50
Low: $3.30
High: $8.15

Volume

1,305,628 shs

Average Volume

879,095 shs

Market Capitalization

$68.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biomerica?

The following Wall Street sell-side analysts have issued research reports on Biomerica in the last year: B. Riley, and Colliers Securities.
View the latest analyst ratings for BMRA.

What is the current price target for Biomerica?

2 Wall Street analysts have set twelve-month price targets for Biomerica in the last year. Their average twelve-month price target is $11.50, suggesting a possible upside of 109.1%. Colliers Securities has the highest price target set, predicting BMRA will reach $13.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $10.00 for Biomerica in the next year.
View the latest price targets for BMRA.

What is the current consensus analyst rating for Biomerica?

Biomerica currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BMRA will outperform the market and that investors should add to their positions of Biomerica.
View the latest ratings for BMRA.

How do I contact Biomerica's investor relations team?

Biomerica's physical mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The company's listed phone number is (949) 645-2111. The official website for Biomerica is www.biomerica.com.